Active Ingredient History
Omega-3 carboxylic acids (Epanova) is a formerly marketed yet still not an Food And Drug Administration (FDA) approved prescription medication–since taken off market by the manufacturer–used alongside a low fat and low cholesterol diet that lowers high triglyceride (fat) levels in adults with very high levels. This was the third class of fish oil-based drug, after omega-3 acid ethyl esters and ethyl eicosapentaenoic acid (Vascepa), to be approved for use as a drug. The first approval by US Food and Drug Administration was granted 05 May 2014. These fish oil drugs are similar to fish oil dietary supplements, but the ingredients are better controlled and have been tested in clinical trials. Specifically, Epanova contained at least 850 mg omega-3-acid ethyl esters per 1 g capsule. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Hypertriglyceridemia (approved 2014)
Area Under Curve (Phase 1)
Atherosclerosis (Phase 3)
Cardiovascular Diseases (Phase 3)
Crohn Disease (Phase 3)
Diabetes Mellitus, Type 2 (Phase 2)
Drugs, Investigational (Phase 1)
Exocrine Pancreatic Insufficiency (Phase 2)
Fasting (Phase 1)
Healthy Volunteers (Phase 1)
Hypertriglyceridemia (Phase 3)
Pharmacokinetics (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
